European Culture Collections’ Organisation (EURO-ECCO)
The aim of the organisation is to promote collaboration and exchange of ideas and information about all aspects of culture collection activity.
Membership location: 61 members from 22 European countries
Membership scope: corporate membership is open to representatives of any microbial resource centre that provides a professional public service on demand and without restriction; that accepts cultures for deposit, provides catalogues of holdings and that is housed in countries with microbiological societies affiliated to the Federation of the European Microbiological Societies (FEMS). In addition, member collections must be registered with the World Federation for Culture Collections (WFCC). The organisation welcomes sustaining and individual members.
|Membership type||fee (currency)||Notes|
|Individual Member||€50 per annum||Membership is open to representatives of any microbial resource centre that provides a professional public service on demand and without restriction. Applications for Membership are made to the Secretary. New members are accepted by exisiting members at the Annual General Meeting (AGM). The candidate members (or Secretary, if not present) introduce themselves at the AGM and their membership is determined by majority vote.|
|Non-commercial corporate member with 1 – 4 fixed full time positions||€50 per annum|
|Non-commercial corporate member with 5 or more fixed full time positions||€200 per annum|
|Commercial Corporate Members||€200 per annum|
How to join
Contact Marijke Hendrickx at firstname.lastname@example.org
Antimicrobial resistance (AMR) is a global problem hindering treatment of bacterial infections, rendering many aspects of modern medicine less effective. AMR genes (ARGs) are frequently located on plasmids, which are self-replicating elements of DNA. They are often transmissible between bacteria, and some have spread globally. Novel strategies to combat AMR are needed, and plasmid curing and anti-plasmid approaches could reduce ARG prevalence, and sensitise bacteria to antibiotics. Currently, there is a general lack of in vivo curing options. This review highlights this important shortfall, which if filled could provide a promising mechanism to reduce ARG prevalence in humans and animals. Plasmid curing mechanisms which are not suitable for in vivo use could still prove important for reducing the global burden of AMR, as high levels of ARGs exist in the environment.